Arius Research Inc.
Records under this name other than patents Arius Research Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,149,792 | Device registration mechanism Formerly held Term ended Term ended Nov 24, 2021 · From the USPTO record | Term ended | Term ended Nov 24, 2021 | From the USPTO record |
| US 7,361,342 | Cancerous Disease Modifying Antibodies Formerly held Term ended Ended no later than Feb 10, 2021 · Low confidence | Term ended | Ended no later than Feb 10, 2021 | Low confidence |
| US 7,442,776 | Cancerous Disease Modifying Antibodies Formerly held Lapsed on the fee record Ended Oct 28, 2020 · Medium confidence | Lapsed on the fee record | Ended Oct 28, 2020 | Medium confidence |
| US 8,277,803 | Cancerous Disease Modifying Antibodies Formerly held Lapsed on the fee record Ended Oct 2, 2020 · High confidence | Lapsed on the fee record | Ended Oct 2, 2020 | High confidence |
| US 7,419,792 | Laminin Receptor 1 Precursor Protein (37LRP) epitope delineated by an Hepatocellular carcinoma specific antibody Formerly held Term ended Term ended Jul 9, 2020 · From the USPTO record | Term ended | Term ended Jul 9, 2020 | From the USPTO record |
| US 7,393,531 | Cytotoxicity Mediation of Cells Evidencing Surface Expression of MCSP Formerly held Lapsed on the fee record Ended Jul 1, 2020 · Low confidence | Lapsed on the fee record | Ended Jul 1, 2020 | Low confidence |
| US 8,129,502 | Cancerous Disease Modifying Antibodies Lapsed on the fee record Ended Mar 6, 2020 · High confidence | Lapsed on the fee record | Ended Mar 6, 2020 | High confidence |
| US 8,071,072 | Cytotoxicity Mediation of Cells Evidencing Surface Expression of CD44 Term ended Term ended Nov 7, 2019 · Medium confidence | Term ended | Term ended Nov 7, 2019 | Medium confidence |
| US 8,048,416 | Cytotoxicity Mediation of Cells Evidencing Surface Expression of CD44 Lapsed on the fee record Ended Nov 1, 2019 · Medium confidence | Lapsed on the fee record | Ended Nov 1, 2019 | Medium confidence |
| US 6,180,357 | Individualized patient-specific anti-cancer antibodies Formerly held Term ended Term ended Oct 8, 2019 · From the USPTO record | Term ended | Term ended Oct 8, 2019 | From the USPTO record |